Valuation: Inventiva

Market Cap 881M 1.01B 813M 751M 1.42B 96.1B 1.45B 9.71B 3.81B 47.34B 3.78B 3.7B 163B P/E 2026 *
-5.11x
P/E 2027 * -5.16x
Enterprise Value 664M 759M 613M 566M 1.07B 72.43B 1.09B 7.32B 2.88B 35.68B 2.85B 2.79B 123B EV / Sales 2026 *
123x
EV / Sales 2027 * 1.24x
Free-Float
89.08%
Yield 2026 *
-
Yield 2027 * -
1 week+9.06%
Current month+15.84%
1 month+9.06%
3 months-17.57%
6 months-15.32%
Current year-5.45%
1 week 3.26
Extreme 3.265
4.04
1 month 2.88
Extreme 2.88
4.04
Current year 2.88
Extreme 2.88
6.2
1 year 2.64
Extreme 2.645
6.2
3 years 1.43
Extreme 1.434
6.2
5 years 1.43
Extreme 1.434
13.18
10 years 1.43
Extreme 1.434
16.3
Manager TitleAgeSince
Chief Executive Officer 53 2025-09-30
Director of Finance/CFO 59 2026-04-21
Chief Tech/Sci/R&D Officer 56 2025-07-29
Director TitleAgeSince
Director/Board Member 75 2017-01-31
Director/Board Member 63 2019-05-26
Director/Board Member 52 2024-04-30
Date Insider Type Main position Quantity % Market Cap.
01-09Others

Chief Operating Officer

25,000 0.0131%
01-09Others

General Counsel

25,000 0.0131%
01-09Others

Executive/Senior Manager

50,000 0.0262%
Change 5-day change 1-year change 3-year change Capi.($)
0.00%+9.06%+34.66%-1.19% 1.01B
+1.84%-0.66%+59.82%+94.48% 54.88B
-4.14%-8.06%+58.96%+125.71% 54.63B
-2.24%+3.59%+17.75%+469.23% 25.06B
-1.60%-6.21%-18.96%-16.06% 23.14B
-1.42%-1.16%+39.66%-8.21% 19.87B
-3.19%0.00%+35.60%-27.49% 17.55B
-6.84%+2.18%+195.12%+364.56% 16.5B
-4.09%-5.67%+44.05%+620.88% 15.75B
-1.05%+1.16%+25.95%+191.69% 14.2B
Average -2.32%+0.66%+49.26%+181.36% 24.26B
Weighted average by Cap. -2.07%-1.41%+50.46%+170.29%

Financials

2026 *2027 *
Net sales 5.42M 6.19M 5M 4.62M 8.76M 591M 8.9M 59.7M 23.45M 291M 23.25M 22.75M 1B 118M 135M 109M 101M 191M 12.89B 194M 1.3B 511M 6.35B 507M 496M 21.82B
Net income -146M -167M -134M -124M -236M -15.89B -239M -1.61B -631M -7.83B -625M -612M -26.91B -86.23M -98.58M -79.54M -73.46M -139M -9.4B -142M -950M -373M -4.63B -370M -362M -15.92B
Net Debt -217M -248M -200M -185M -351M -23.66B -357M -2.39B -939M -11.66B -932M -911M -40.07B -734M -840M -677M -626M -1.19B -80.09B -1.21B -8.09B -3.18B -39.45B -3.15B -3.08B -136B
Logo Inventiva
Inventiva is a clinical-stage biopharmaceutical company focused on the research and development of oral small molecule therapies for the treatment of patients with MASH and other diseases with significant unmet medical need. The Company is currently evaluating lanifibranor, a novel pan-PPAR agonist, in the NATiV3 pivotal Phase 3 clinical trial for the treatment of adult patients with MASH, a common and progressive chronic liver disease. Inventiva owns an extensive library of approximately 240,000 pharmacologically relevant molecules, approximately 60% of which are proprietary, as well as a wholly owned research and development facility.
Employees
73
Date Price Change Volume
26-07-10 €3.730 0.00% 451,050
26-07-09 €3.730 -0.80% 322,749
26-07-08 €3.760 +13.08% 1,081,431
26-07-07 €3.325 -2.64% 179,285
26-07-06 €3.415 -0.15% 279,574
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
3.730EUR
Average target price
9.634EUR
Spread / Average Target
+158.29%

Quarterly revenue - Rate of surprise